Tech Company Financing Transactions
Wilson Therapeutics Funding Round
Wilson Therapeutics, based in Burlington, secured $40 million in investment from Abingworth and Healthcap Venture Capital.
Transaction Overview
Company Name
Announced On
4/17/2014
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series B
Investors
Abingworth (Lead Investor) (Genghis Lloyd-Harris)
Proceeds Purpose
Wilson Therapeutics will use the funding to advance clinical development of a new treatment for Wilson's disease, a rare genetic disorder that prevents the body from regulating copper and can lead to liver and brain damage.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1500 District Ave.
Burlington, MA 01803
USA
Burlington, MA 01803
USA
Phone
Undisclosed
Website
Email Address
Overview
Wilson Therapeutics AB is a privately-held biopharmaceutical company focused on developing novel treatments for Wilson Disease, a rare genetic disease that affects approximately 1 in 15,000. Wilson Therapeutics was founded in 2012 and is backed by HealthCap, one of the leading European life science venture capital funds.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jonas Hansson
Chief Financial Officer
Anders Martin-Löf
Chief Medical Officer
Carl Bjartmar
Chief Scientific Officer
Thomas Plitz
VP - Manufacturing
Lars Olsson
Browse more venture capital transactions:
Prev: 4/17/2014: eCaring venture capital transaction
Next: 4/17/2014: Axial Exchange venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs